Prescription Drugs

CLINICAL PHARMACOLOGY No information provided.

CLINICAL PHARMACOLOGY Mechanism Of Action HUMULIN N lowers blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis. Pharmacodynamics HUMULIN N is an intermediate-acting insulin with a slower onset of action and a longer duration of activity than that of regular human insulin. In a study in which healthy subjects (n=16) received subcutaneous injections of HUMULIN N (0.4 unit/kg) on 4 occasions, the median maximum effect occurred at 6.5 hours (range: 2.8 to 13 hours). In this study, insulin activity was measured by the rate of glucose infusions. The time course of action of insulin, such as HUMULIN N may vary in different individuals or within the same individual. The parameters of HUMULIN N activity (time of onset, peak time, and duration) as designated in Figure 1 should be considered only as general guidelines. The rate of insulin absorption and consequently the onset of activity is known to be affected by the site of injection, physical activity level, and other variables [see WARNINGS AND PRECAUTIONS]. Figure 1: Mean Insulin Activity Versus Time Profile After Subcutaneous Injection of HUMULIN N (0.4 unit/kg) in Healthy Subjects. Pharmacokinetics Absorption In healthy subjects given subcutaneous doses of HUMULIN N (0.4 unit/kg), median peak serum concentration of insulin occurred at approximately 4 hours (range: 1 to 12 hours) after dosing. Metabolism The uptake and degradation of insulin occurs predominantly in liver, kidney, muscle, and adipocytes, with the liver being the major organ involved in the clearance of insulin. Elimination Because of the absorption-rate limited kinetics of insulin mixtures, a true half-life cannot be accurately estimated from the terminal slope of the concentration versus time curve. In healthy subjects given subcutaneous doses of HUMULIN N (0.4 unit/kg), the mean apparent half-life was approximately 4.4 hours (range: 1-84 hours). Specific Populations The effects of age, gender, race, obesity, pregnancy, or smoking on the pharmacokinetics of HUMULIN N have not been studied. Careful glucose monitoring and dose adjustments of insulin, including HUMULIN N, may be necessary in patients with renal or hepatic dysfunction [see Use In Specific Populations].

CLINICAL PHARMACOLOGY Mechanism Of Action HUMULIN 70/30 lowers blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis. Pharmacodynamics HUMULIN 70/30 combines an intermediate-acting insulin with the more rapid onset of action of regular human insulin. In healthy males (n=18) given HUMULIN 70/30 (0.3 unit/kg) subcutaneously, the pharmacologic effect began at approximately 50 minutes (range: 30 to 90 minutes) (see Figure 1). The effect was maximal at approximately 3.5 hours (range: 1.5 to 6.5 hours) and the mean duration of action was relatively long (approximately 23 hours; range: 18-24 hours). Figure 1 should be considered only as a representative example since the time course of action of insulin may vary in different individuals or within the same individual. The rate of insulin absorption and consequently the onset of activity is known to be affected by the site of injection, physical activity level, and other variables [see WARNINGS AND PRECAUTIONS]. Figure 1: Mean Insulin Activity Versus Time Profiles After Subcutaneous Injection of HUMULIN 70/30 or HUMULIN® R U-100 (0.3 unit/kg) in Healthy Subjects. Pharmacokinetics Absorption In healthy male subjects given HUMULIN 70/30 (0.3 unit/kg) subcutaneously, the mean peak serum concentration occurred at 2.2 hours (range: 1 to 5 hours) after dosing. Metabolism The uptake and degradation of insulin occurs predominantly in liver, kidney, muscle, and adipocytes, with the liver being the major organ involved in the clearance of insulin. Elimination Because of the absorption-rate limited kinetics of insulin mixtures, a true half-life cannot be accurately estimated from the terminal slope of the concentration versus time curve. Specific Populations The effects of age, gender, race, obesity, pregnancy, or smoking on the pharmacokinetics of HUMULIN 70/30 have not been studied. Careful glucose monitoring and dose adjustments of insulin, including HUMULIN 70/30, may be necessary in patients with renal or hepatic dysfunction [see Use In Specific Populations].

Find Lowest Prices on HUMULIN®R (regular insulin human) Injection, USP (rDNA Origin) 100 Units per ML (U-100) DESCRIPTION Humulin® R U-100 is a polypeptide hormone structurally identical to human insulin synthesized through rDNA technology in a special non-disease-producing laboratory strain of Escherichia coli bacteria. Humulin R (insulin human recombinant) U-100 has the empirical formula C257H383N65O77S6 and a molecular weight of 5808. Humulin R (insulin human recombinant) U-100 is a sterile, clear, aqueous, and colorless solution that contains human insulin (rDNA origin) 100 units/mL, glycerin 16 mg/mL and metacresol 2.5 mg/mL, endogenous zinc (approximately 0.015 mg/100 units) and water for injection. The pH is 7.0 to 7.8. Sodiumhydroxide and/or hydrochloric acid may be added during manufacture to adjust the pH. Adequate insulin dosage permits patients with diabetes to effectively utilize carbohydrates, proteins and fats. Regardless of dose strength, insulin enables carbohydrate metabolism to occur and thus to prevent the production of ketone bodies by the liver. Some patients develop severe insulin resistance such that daily doses of several hundred units of insulin or more are required.

Find Lowest Prices on HUMULIN® N (human insulin [rDNA origin]) isophane) Suspension DESCRIPTION HUMULIN N (human insulin [rDNA origin] isophane) suspension is a human insulin suspension. Human insulin is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli. HUMULIN N is a suspension of crystals produced from combining human insulin and protamine sulfate under appropriate conditions for crystal formation. The amino acid sequence of HUMULIN N is identical to human insulin and has the empirical formula C257H383N65O77S6 with a molecular weight of 5808. HUMULIN N is a sterile white suspension. Each milliliter of HUMULIN N contains 100 units of insulin human, 0.35 mg of protamine sulfate, 16 mg of glycerin, 3.78 mg of dibasic sodium phosphate, 1.6 mg of metacresol, 0.65 mg of phenol, zinc oxide content adjusted to provide 0.025 mg zinc ion, and Water for Injection. The pH is 7.0 to 7.5. Sodium hydroxide and/or hydrochloric acid may be added during manufacture to adjust the pH.

Find Lowest Prices on HUMULIN® 70/30 (70% human insulin isophane) Suspension and (30% human insulin) Injection, [rDNA origin] DESCRIPTION HUMULIN 70/30 (70% human insulin isophane suspension and 30% human insulin injection [rDNA origin]) is a human insulin suspension. Human insulin is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli. HUMULIN 70/30 is a suspension of crystals produced from combining human insulin and protamine sulfate under appropriate conditions for crystal formation and mixing with human insulin injection. The amino acid sequence of HUMULIN 70/30 is identical to human insulin and has the empirical formula C257H383N65O77S6 with a molecular weight of 5808. HUMULIN 70/30 is a sterile white suspension. Each milliliter of HUMULIN 70/30 contains 100 units of insulin human, 0.24 mg of protamine sulfate, 16 mg of glycerin, 3.78 mg of dibasic sodium phosphate, 1.6 mg of metacresol, 0.65 mg of phenol, zinc oxide content adjusted to provide 0.025 mg zinc ion, and Water for Injection. The pH is 7.0 to 7.8. Sodium hydroxide and/or hydrochloric acid may be added during manufacture to adjust the pH.

INDICATIONS Humulin R (insulin (human recombinant)) U-100 is indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 1 and type 2 diabetes mellitus. Humulin R (insulin (human recombinant)) U-100 may be administered intravenously under proper medical supervision in a clinical setting for glycemic control (see DOSAGE AND ADMINISTRATION and Storage). DOSAGE AND ADMINISTRATION Humulin R (insulin (human recombinant)) U-100, when used subcutaneously, is usually given three or more times daily before meals. The dosage and timing of Humulin R (insulin (human recombinant)) U-100 should be individualized and determined, based on the physician's advice, in accordance with the needs of the patient. Humulin R (insulin (human recombinant)) U-100 may also be used in combination with oral antihyperglycemic agents or longer-acting insulin products to suit the needs of the individual patients with diabetes. The injection of Humulin R (insulin (human recombinant)) U-100 should be followed by a meal within approximately 30 minutes of administration. The average range of total daily insulin requirement for maintenance therapy in insulin-treated patients without severe insulin resistance lies between 0.5 and 1 unit/kg/day. However, in prepubertal children it usually varies from 0.7 to 1 unit/kg/day, but can be much lower during the period of partial remission. In situations of insulin resistance, e.g. during puberty or due to obesity, the daily insulin requirement may be substantially higher. Initial dosages for patients with diabetes are often lower, e.g., 0.2 to 0.4 units/kg/day. Humulin R (insulin (human recombinant)) U-100 may be administered by subcutaneous injection in the abdominal wall, the thigh, the gluteal region or in the upper arm. Subcutaneous injection into the abdominal wall ensures a faster absorption than from other injection sites. Injection into a lifted skin fold minimizes the risk of intramuscular injection. Injection sites should be rotated within the sameregion. As with all insulin, the duration of action will vary according to the dose, injection site, blood flow, temperature, and level of physical activity. Intravenous administration of Humulin R (insulin (human recombinant)) U-100 is possible under medical supervision with close monitoring of blood glucose and potassium levels to avoid hypoglycemia and hypokalemia. For intravenous use, Humulin R (insulin (human recombinant)) U-100 should be used at concentrations from 0.1 unit/mL to 1 unit/mL in infusion systems with the infusion fluids 0.9% sodium chloride using polyvinyl chloride infusion bags. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Never use Humulin R (insulin (human recombinant)) U-100 if it has become viscous (thickened) or cloudy; use it only if it is clear and colorless. Humulin R (insulin (human recombinant)) U-100 should not be used after the printed expiration date. Mixing of Insulins Humulin R (insulin (human recombinant)) U-100 should only be mixed as directed by the physician Humulin R (insulin (human recombinant)) U-100 is short-acting and is often used in combination with intermediate- or long-acting insulins. The order of mixing and brand or model of syringe should be specified by the physician. A U-100 insulin syringe should always be used. Failure to use the correct syringe can lead to dosage errors. In general, when an intermediate-acting insulin (e.g., NPH insulin isophane suspension) is mixed with short-acting soluble insulin (e.g., regular), the short-acting insulin should be drawn into the syringe first. Storage Not in-use (unopened): Humulin R (insulin (human recombinant)) U-100 vials not in-use should be stored in a refrigerator (2° to 8°C [36° to 46°F]), but not in the freezer. In-use (opened): The Humulin R (insulin (human recombinant)) U-100 vial currently in-use can be kept unrefrigerated as long as it is kept as cool as possible [below 30°C (86°F)] away from heat and light. In-use vials must be used within 31 days or be discarded, even if they still contain Humulin R (insulin (human recombinant)) U-100. Admixture: Infusion bags prepared with Humulin R (insulin (human recombinant)) U-100 as indicated under DOSAGE AND ADMINISTRATION are stable when stored in a refrigerator (2° to 8°C [36° to 46°F]) for 48 hours and then may be used at room temperature for up to an additional 48 hours. Do not use Humulin R (insulin (human recombinant)) U-100 after the expiration date stamped on the label or if it has been frozen. HOW SUPPLIED Humulin R (insulin (human recombinant)) U-100, Regular, insulin human injection, USP (rDNA origin), 100 units/mL, is supplied as follows: 10 mL vials NDC 0002-8215-01 (HI-210) 3 mL vials NDC 0002-8215-17 (HI-213) Literature issued March, 2011. Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA

INDICATIONS HUMULIN N is an intermediate-acting recombinant human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. DOSAGE AND ADMINISTRATION Important Administration Instructions Inspect HUMULIN N visually before use. It should not contain particulate matter and should appear uniformly cloudy after mixing. Do not use HUMULIN N if particulate matter is seen. Route of Administration HUMULIN N should only be administered subcutaneously. Administer in the subcutaneous tissue of the abdominal wall, thigh, upper arm, or buttocks. To reduce the risk of lipodystrophy, rotate the injection site within the same region from one injection to the next [see ADVERSE REACTIONS]. Do not administer HUMULIN N intravenously or intramuscularly and do not use HUMULIN N in an insulin infusion pump. Dosage Information Individualize and adjust the dosage of HUMULIN N based on the individual's metabolic needs, blood glucose monitoring results and glycemic control goal. Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function or during acute illness [see WARNINGS AND PRECAUTIONS, and Use In Specific Populations]. Dosage Adjustment Due To Drug Interactions Dosage adjustment may be needed when HUMULIN N is coadministered with certain drugs [see DRUG INTERACTIONS]. Dosage adjustment may be needed when switching from another insulin to HUMULIN N [see WARNINGS AND PRECAUTIONS]. Instructions for Mixing with Other Insulins HUMULIN N may be used with a prandial insulin if indicated. HUMULIN N may be mixed with HUMULIN R or HUMALOG before injection. If HUMULIN N is mixed with HUMULIN R, HUMULIN R should be drawn into the syringe first. Injection should occur immediately after mixing. If HUMULIN N is mixed with HUMALOG, HUMALOG should be drawn into the syringe first. Injection should occur immediately after mixing. HOW SUPPLIED Dosage Forms And Strengths HUMULIN N injectable suspension: 100 units per mL (U-100) is available as: 10 mL vials 3 mL prefilled pens HUMULIN N 100 units per mL (U-100) is available as: 10 mL vials NDC 0002-8315-01 (HI-310) 5 x 3 mL prefilled pen NDC 0002-8730-59 (HP-8730) Storage And Handling Protect from heat and light. Do not freeze. Do not use after the expiration date. Not In-Use (Unopened) HUMULIN N Vials Refrigerated Store in a refrigerator (36° to 46°F [2° to 8°C]), but not in the freezer. Do not use if it has been frozen. Room Temperature If stored at room temperature, below 86°F (30°C) the vial must be discarded after 31days. In-Use (Opened) HUMULIN N Vials Refrigerated Store in a refrigerator (36° to 46°F [2° to 8°C]), but not in the freezer. Do not use if it has been frozen. Vials must be used within 31 days or be discarded, even if they still contain HUMULIN N. Room Temperature If stored at room temperature, below 86°F (30°C) the vial must be discarded after 31 days, even if the vial still contains HUMULIN N. Not In-Use (Unopened) HUMULIN N Pen Refrigerated Store in a refrigerator (36° to 46°F [2° to 8°C]), but not in the freezer. Do not use if it has been frozen. Room Temperature If stored at room temperature, below 86°F (30°C) the pen must be discarded after 14 days. In-Use (Opened) HUMULIN N Pen Refrigerated Do NOT store in a refrigerator. Room Temperature Store at room temperature, below 86°F (30°C) and the pen must be discarded after 14 days, even if the pen still contains HUMULIN N. See storage table below: Not In-Use (Unopened) Refrigerated Not In-Use (Unopened) Room Temperature In-Use (Opened) 10 mL vial Until expiration date 31 days 31 days, refrigerated/room temperature 3 mL pen Until expiration date 14 days 14 days, room temperature. Do not refrigerate. Marketed by: Lilly USA, LLC Indianapolis, IN 46285, USA

INDICATIONS HUMULIN 70/30 is a fixed ratio premix recombinant human insulin formulation indicated to improve glycemic control in adult patients with diabetes mellitus. DOSAGE AND ADMINISTRATION Important Administration Instructions Inspect HUMULIN 70/30 visually before use. It should not contain particulate matter and should appear uniformly cloudy after mixing. Do not use HUMULIN 70/30 if particulate matter is seen. Do not mix HUMULIN 70/30 with any other insulins or diluents. Route Of Administration HUMULIN 70/30 should only be administered subcutaneously. Administer in the subcutaneous tissue of the abdominal wall, thigh, upper arm, or buttocks. To reduce the risk of lipodystrophy, rotate the injection site within the same region from one injection to the next [see ADVERSE REACTIONS]. Do not administer HUMULIN 70/30 intravenously or intramuscularly and do not use HUMULIN 70/30 in an insulin infusion pump. Dosage Information Individualize and adjust the dosage of HUMULIN 70/30 based on the individual's metabolic needs, blood glucose monitoring results and glycemic control goal. Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function or during acute illness [see WARNINGS AND PRECAUTIONS, and Use in Specific Populations]. The proportion of rapid acting and long acting insulin is fixed in a premixed insulin such as HUMULIN 70/30. Independent adjustment of the basal or prandial dose is not possible when using a premixed insulin. Physiological factors, disease states and concomitant drugs may impact the onset and duration of action of all insulins. HUMULIN 70/30 dose requirements may change with changes in level of physical activity, meal patterns (i.e., macronutrient content or timing of food intake), during major illness, or with some coadministered drugs [see WARNINGS AND PRECAUTIONS, DRUG INTERACTIONS, and Use In Specific Populations]. Timing Of Subcutaneous Administration HUMULIN 70/30 should be given subcutaneously approximately 30-45 minutes before a meal. HOW SUPPLIED Dosage Forms And Strengths HUMULIN 70/30 injectable suspension: 100 units per mL (U-100) is available as: 10 mL vials 3 mL vials 3 mL prefilled pens HUMULIN 70/30 100 units per mL (U-100) is available as: 10 mL vials NDC 0002-8715-01 (HI-710) 3 mL vials NDC 0002-8715-17 (HI-713) 5 x 3 mL prefilled pen NDC 0002-8770-59 (HP-8770) Storage And Handling Protect from heat and light. Do not freeze. Do not use after the expiration date. Not In-Use (Unopened) HUMULIN 70/30 Vials Refrigerated Store in a refrigerator (36° to 46°F [2° to 8°C]), but not in the freezer. Do not use if it has been frozen. Room Temperature If stored at room temperature, below 86°F (30°C) the vial must be discarded after 31days. In-Use (Opened) HUMULIN 70/30 Vials Refrigerated Store in a refrigerator (36° to 46°F [2° to 8°C]), but not in the freezer. Do not use if it has been frozen. Vials must be used within 31 days or be discarded, even if they still contain HUMULIN 70/30. Room Temperature If stored at room temperature, below 86°F (30°C) the vial must be discarded after 31 days, even if the vial still contains HUMULIN 70/30. Not In-Use (Unopened) HUMULIN 70/30 Pen Refrigerated Store in a refrigerator (36° to 46°F [2° to 8°C]), but not in the freezer. Do not use if it has been frozen. Room Temperature If stored at room temperature, below 86°F (30°C) the pen must be discarded after 10 days. In-Use (Opened) HUMULIN 70/30 Pen Refrigerated Do NOT store in a refrigerator. Room Temperature Store at room temperature, below 86°F (30°C) and the pen must be discarded after 10 days, even if the pen still contains HUMULIN 70/30. See storage table below: Not In-Use (Unopened) Refrigerated Not In-Use (Unopened) Room Temperature In-Use (Opened) 10 mL vial 3 mL vial Until expiration date 31 days 31 days, refrigerated/room temperature 3 mL pen Until expiration date 10 days 10 days, room temperature. Do not refrigerate. Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA. Revised: Nov 2013

PATIENT INFORMATION HUMULIN® (HU-mu-lin) N (human insulin [rDNA origin] isophane) Suspension What is HUMULIN N? HUMULIN N is a man-made insulin that is used to control high blood sugar in adults and children with diabetes mellitus. Who should not use HUMULIN N? Do not use HUMULIN N if you: are having an episode of low blood sugar (hypoglycemia). have an allergy to HUMULIN N or any of the ingredients in HUMULIN N. Before using HUMULIN N, tell your healthcare provider about all your medical conditions including, if you: have liver or kidney problems. take any other medicines, especially ones commonly called TZDs (thiazolidinediones). have heart failure or other heart problems. If you have heart failure, it may get worse while you take TZDs with HUMULIN N. are pregnant, planning to become pregnant, or are breastfeeding. are taking new prescription or over-the-counter medicines, vitamins, or herbal supplements. Before you start using HUMULIN N, talk to your healthcare provider about low blood sugar and how to manage it. How should I use HUMULIN N? Read the Instructions for Use that come with your HUMULIN N. Use HUMULIN N exactly as your healthcare provider tells you to. Know the type and strength of insulin you use. Do not change the type of insulin you use unless your healthcare provider tells you to. The amount of insulin and the best time for you to take your insulin may need to change if you use different types of insulin. Check your blood sugar levels. Ask your healthcare provider what your blood sugars should be and when you should check your blood sugar levels. Your HUMULIN N dose may need to change because of: change in level of physical activity or exercise, weight gain or loss, increased stress, illness, change in diet. What should I avoid while using HUMULIN N? While using HUMULIN N do not: Drive or operate heavy machinery, until you know how HUMULIN N affects you. Drink alcohol or use prescription or over-the-counter medicines that contain alcohol. What are the possible side effects of HUMULIN N? HUMULIN N may cause serious side effects that can lead to death, including: low blood sugar (hypoglycemia). Signs and symptoms that may indicate low blood sugar include: dizziness or light-headedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, or mood changes, hunger. serious allergic reaction (whole body reaction). Get medical help right away, if you have any of these symptoms of an allergic reaction: a rash over your whole body, trouble breathing, a fast heartbeat, or sweating. low potassium in your blood (hypokalemia). heart failure. Taking certain diabetes pills called thiazolidinediones or “TZDs” with HUMULIN N may cause heart failure in some people. This can happen even if you have never had heart failure or heart problems before. If you already have heart failure it may get worse while you take TZDs with HUMULIN N. Your healthcare provider should monitor you closely while you are taking TZDs with HUMULIN N. Tell your healthcare provider if you have any new or worse symptoms of heart failure including: shortness of breath, swelling of your ankles or feet, sudden weight gain Treatment with TZDs and HUMULIN N may need to be adjusted or stopped by your healthcare provider if you have new or worse heart failure. Get emergency medical help if you have: trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, confusion. The most common side effects of HUMULIN N include: low blood sugar (hypoglycemia), allergic reactions including reactions at the injection site, skin thickening or pits at the injection site (lipodystrophy), itching, rash, weight gain, and swelling of your hands and feet. These are not all the possible side effects of HUMULIN N. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. General information about the safe and effective use of HUMULIN N: Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about HUMULIN N that is written for health professionals. Do not use HUMULIN N for a condition for which it was not prescribed. Do not give HUMULIN N to other people, even if they have the same symptoms that you have. It may harm them. What are the ingredients in HUMULIN N? Active Ingredient: insulin human (rDNA origin) Inactive Ingredients: protamine sulfate, glycerin, dibasic sodium phosphate, metacresol, phenol, zinc oxide, water for injection, hydrochloric acid or sodium hydroxide For more information, call 1-800-545-5979 or go to www.humulin.com. This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: Month DD, YYYY Instructions for Use HUMULIN® (HU-mu-lin) N (human insulin [rDNA origin] isophane suspension) vial (100 Units/mL, U-100) Read the Instructions for Use before you start taking HUMULIN N and each time you get a new HUMULIN N vial. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. Do not share your syringes or needles with anyone else. You may give an infection to them or get an infection from them. Supplies needed to give your injection: a HUMULIN N vial a U-100 insulin syringe and needle 2 alcohol swabs 1 sharps container for throwing away used needles and syringes. See “Disposing of used needles and syringes” at the end of these instructions. Preparing your HUMULIN N dose: Wash your hands with soap and water. Check the HUMULIN N label to make sure you are taking the right type of insulin. This is especially important if you use more than 1 type of insulin. Do not use HUMULIN N past the expiration date printed on the label or 31 days after you first use it. Always use a new needle for each injection to help ensure sterility and prevent blocked needles. Step 1: Gently roll the vial between the palms of your hands at least 10 times. Step 2: Invert the vial at least 10 times. Do not shake. Mixing is important to make sure you get the right dose. Humulin N should look white and cloudy after mixing. Do not use it if it looks clear or contains any lumps or particles. Step 3: If you are using a new vial, pull off the plastic Protective Cap, but do not remove the Rubber Stopper. Step 4: Wipe the Rubber Stopper with an alcohol swab. Step 5: Hold the syringe with the needle pointing up. Pull down on the Plunger until the tip of the Plunger reaches the line for the number of units for your prescribed dose. (Example Dose: 20 units shown) Step 6: Push the needle through the Rubber Stopper of the vial. Step 7: Push the plunger all the way in. This puts air into the vial. Step 8: Turn the vial and syringe upside down and slowly pull the Plunger down until the tip is a few units past the line for your prescribed dose. (Example Dose: 20 units Plunger is shown at 24 units) If there are air bubbles, tap the syringe gently a few times to let any air bubbles rise to the top. Step 9: Slowly push the Plunger up until the tip reaches the line for your prescribed dose. Check the syringe to make sure that you have the right dose. (Example Dose: 20 units shown) Step 10: Pull the syringe out of the vial's Rubber Stopper. Giving your HUMULIN N injection: Inject your insulin exactly as your healthcare provider has shown you. Change (rotate) your injection site for each injection. Step 11: Choose your injection site. HUMULIN N is injected under the skin (subcutaneously) of your stomach area (abdomen), buttocks, upper legs or upper arms. Wipe the skin with an alcohol swab. Let the injection site dry before you inject your dose. Step 12: Insert the needle into your skin. Step 13: Push down on the Plunger to inject your dose. The needle should stay in your skin for at least 5 seconds to make sure you have injected all of your insulin dose. Step 14: Pull the needle out of your skin. If you see blood after you take the needle out of your skin, press the injection site with a piece of gauze or an alcohol swab. Do not rub the area. Do not recap the needle. Recapping the needle can lead to a needle stick injury. Disposing of used needles and syringes: Put your used needles and syringes in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles and syringes in your household trash. If you do not have a FDA-cleared sharps disposal container, you may use a household container that is: made of a heavy-duty plastic, can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, upright and stable during use, leak-resistant, and properly labeled to warn of hazardous waste inside the container. When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal Do not recycle the container. How should I store HUMULIN N? All unopened HUMULIN N vials: Store all unopened vials in the refrigerator. Do not freeze. Do not use if it has been frozen. Keep away from heat and out of direct light. Unopened vials can be used until the expiration date on the carton and label, if they have been stored in the refrigerator. Unopened vials should be thrown away after 31 days, if they are stored at room temperature. After HUMULIN N vials have been opened: Store opened vials in the refrigerator or at room temperature below 86°F (30°C) for up to 31 days. Keep away from heat and out of direct light. Throw away all opened vials after 31 days of use, even if there is still insulin left in the vial. General information about the safe and effective use of HUMULIN N. Keep HUMULIN N vials, syringes, needles, and all medicines out of the reach of children. If you have any questions or problems with your HUMULIN, contact Lilly at 1-800Lilly-Rx (1-800-545-5979) or call your healthcare provider for help. For more information on HUMULIN and insulin, go to www.humulin.com. Scan this code to launch the humulin.com website This Instructions for Use has been approved by the U.S. Food and Drug Administration. Instructions for Use HUMULIN® N KwikPen™ (human insulin [rDNA origin] isophane suspension) Read the Instructions for Use before you start taking HUMULIN N and each time you get another HUMULIN® N KwikPen™. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. HUMULIN N KwikPen (“Pen”) is a disposable pen containing 3 mL (300 units) of U100 HUMULIN® N (human insulin isophane suspension [rDNA origin]) insulin. You can inject from 1 to 60 units in a single injection. HUMULIN N KwikPen has a blue and light green Label with a matching light green Dose Knob (See the KwikPen Parts diagram below). Do not share your HUMULIN N KwikPen or needles with another person. You may give an infection to them or get an infection from them. This Pen is not recommended for use by the blind or visually impaired without the assistance of a person trained in the proper use of the product. KwikPen Parts Supplies you will need to give your HUMULIN N injection: HUMULIN N KwikPen KwikPen compatible Needle (Becton, Dickinson and Company Pen Needles recommended) alcohol swab Preparing HUMULIN N KwikPen: Wash your hands with soap and water. Check the HUMULIN N KwikPen Label to make sure you are taking the right type of insulin. This is especially important if you use more than 1 type of insulin. Do not use HUMULIN N past the expiration date printed on the Label or 14 days after you start using the Pen. Always use a new needle for each injection to help ensure sterility and prevent blocked needles. Step 1: Pull the Pen Cap straight off. Wipe the Rubber Seal with an alcohol swab. Do not twist the cap. Do not remove the HUMULIN N KwikPen Label. Do not attach the Needle before mixing. Step 2: Gently roll the Pen between your hands 10 times. Step 3: Move the Pen up and down (invert) the Pen 10 times. Mixing by rolling and inverting the Pen is important to make sure you get the right dose. Step 4: Check the liquid in the Pen. HUMULIN N should look white and cloudy after mixing. Do not use if it looks clear or has any lumps or particles in it. Step 5: Select a new Needle. Pull off the Paper Tab from the Outer Needle Shield. Step 6: Push the capped Needle straight onto the Pen and twist the Needle on until it is tight. Step 7: Pull off the Outer Needle Shield. Do not throw it away. Pull off the Inner Needle Shield and throw it away. Priming the HUMULIN N KwikPen: Prime the HUMULIN N KwikPen before each injection. Priming ensures the Pen is ready to dose and removes air that may collect in the cartridge during normal use. If you do not prime before each injection, you may get too much or too little insulin. Step 8: Turn the Dose Knob to select 2 units. Step 9: Hold the Pen with the Needle pointing up. Tap the Cartridge Holder gently to collect air bubbles at the top. Step 10: Hold the Pen with Needle pointing up. Push the Dose Knob in until it stops, and “0” is seen in the Dose Window. Hold the Dose Knob in and count to 5 slowly. A stream of insulin should be seen from the needle. If you do not see a stream of insulin, repeat steps 8 to 10, no more than 4 times. If you still do not see a stream of insulin, change the needle and repeat steps 8 to 10. Selecting your dose: Step 11: Turn the Dose Knob to select the number of units you need to inject. The Dose Indicator should line up with your dose. The dose can be corrected by turning the Dose Knob in either direction until the correct dose lines up with the Dose Indicator. The even numbers are printed on the dial. (Example: 10 units shown) The odd numbers, after the number 1, are shown as full lines. (Example: 15 units shown) The HUMULIN N KwikPen will not let you dial more than the number of units left in the Pen. If your dose is more than the number of units left in the Pen, you may either: inject the amount left in your Pen and then use a new Pen to give the rest of your dose, or get a new Pen and inject the full dose. The Pen is designed to deliver a total of 300 units of insulin. The cartridge contains an additional small amount of insulin that cannot be delivered. Giving your HUMULIN N injection: Inject your HUMULIN N exactly as your healthcare provider has shown you. Change (rotate) your injection site for each injection. Do not try to change your dose while injecting HUMULIN N. Step 12: Choose your injection site. HUMULIN N is injected under the skin (subcutaneously) of your stomach area, buttocks, upper legs or upper arms. Wipe the skin with an alcohol swab, and let the injection site dry before you inject your dose. Step 13: Insert the Needle into your skin. Step 14: Put your thumb on the Dose Knob and push the Dose Knob in until it stops. Hold the Dose Knob in and slowly count to 5. Step 15: Pull the Needle out of your skin. You should see “0” in the Dose Window. If you do not see “0” in the Dose Window, you did not receive your full dose. If you see blood after you take the Needle out of your skin, press the injection site lightly with a piece of gauze or an alcohol swab. Do not rub the area. A drop of insulin at the needle tip is normal. It will not affect your dose. If you do not think you received your full dose, do not take another dose. Call Lilly at 1-800-LillyRx (1-800-545-5979) or your healthcare provider for help. Step 16: Carefully replace the Outer Needle Shield. Step 17: Unscrew the capped Needle and throw it away. Do not store the Pen with the Needle attached to prevent leaking, blocking of the Needle, and air from entering the Pen. Step 18: Replace the Pen Cap by lining up the Cap Clip with the Dose Indicator and pushing straight on. After your injection: Put your used needles and pens in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles and pens in your household trash. If you do not have a FDA-cleared sharps disposal container, you may use a household container that is: made of a heavy-duty plastic, can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, upright and stable during use, leak-resistant, and properly labeled to warn of hazardous waste inside the container. When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal How should I store my HUMULIN N KwikPen? Store unused HUMULIN N KwikPens in the refrigerator at 36°F to 46°F (2°C to 8°C). The Pen you are currently using should be stored at room temperature, below 86°F (30°C). Do not freeze HUMULIN N. Do not use HUMULIN N if it has been frozen. Unused Pens may be used until the expiration date printed on the Label, if kept in the refrigerator. The HUMULIN N Pen you are using should be thrown away after 14 days, even if it still has insulin left in it. Keep HUMULIN N away from heat and out of the light. General information about the safe and effective use of HUMULIN N KwikPen. Keep HUMULIN N KwikPen and needles out of the reach of children. Do not use the Pen if any part looks broken or damaged. Always carry an extra Pen in case yours is lost or damaged. If you cannot remove the Pen Cap, gently twist the Pen Cap back and forth, and then pull the Pen Cap straight off. If it is hard to push the Dose Knob or the Pen is not working the right way: Your Needle may be blocked. Put on a new Needle and prime the Pen. You may have dust, food, or liquid inside the Pen. Throw the Pen away and get a new one. It may help to push the Dose Knob more slowly during your injection. Use the space below to keep track of how long you should use each HUMULIN N KwikPen. Write down the date you start using your HUMULIN N KwikPen. Count forward 14 days. Write down the date you should throw it away. Example: First used on _______ + 14 days = Throw out on ______ __________________Date_____________________ Date Pen 1 -First used on _______ Throw out on _______ __________________Date_____________________ Date Pen 2 -First used on _______ Throw out on _______ __________________Date_____________________ Date Pen 3 -First used on _______ Throw out on _______ __________________Date_____________________ Date Pen 4 -First used on _______ Throw out on _______ __________________Date_____________________ Date Pen 5 -First used on _______ Throw out on _______ __________________Date_____________________ Date If you have any questions or problems with your HUMULIN N KwikPen, contact Lilly at 1-800-LillyRx (1-800-545-5979) or call your healthcare provider for help. For more information on HUMULIN N KwikPen and insulin, go to www.lilly.com. This Instructions for Use has been approved by the U.S. Food and Drug Administration.

PATIENT INFORMATION HUMULIN® (HU-mu-lin) 70/30 (70% human insulin isophane) Suspension and (30% human insulin) Injection [rDNA origin] What is HUMULIN 70/30? HUMULIN 70/30 is a man-made insulin that is used to control high blood sugar in adults with diabetes mellitus. Who should not use HUMULIN 70/30? Do not use HUMULIN 70/30 if you: are having an episode of low blood sugar (hypoglycemia). have an allergy to HUMULIN 70/30 or any of the ingredients in HUMULIN 70/30. Before using HUMULIN 70/30, tell your healthcare provider about all your medical conditions including, if you: have liver or kidney problems. take any other medicines, especially ones commonly called TZDs (thiazolidinediones). have heart failure or other heart problems. If you have heart failure, it may get worse while you take TZDs with HUMULIN 70/30. are pregnant, planning to become pregnant, or are breastfeeding. are taking new prescription or over-the-counter medicines, vitamins, or herbal supplements. Before you start using HUMULIN 70/30, talk to your healthcare provider about low blood sugar and how to manage it. How should I use HUMULIN 70/30? Read the Instructions for Use that come with your HUMULIN 70/30. Use HUMULIN 70/30 exactly as your healthcare provider tells you to. Know the type and strength of insulin you use. Do not change the type of insulin you use unless your healthcare provider tells you to. The amount of insulin and the best time for you to take your insulin may need to change if you use different types of insulin. Check your blood sugar levels. Ask your healthcare provider what your blood sugars should be and when you should check your blood sugar levels. Your HUMULIN 70/30 dose may need to change because of: change in level of physical activity or exercise, weight gain or loss, increased stress, illness, change in diet. What should I avoid while using HUMULIN 70/30? While using HUMULIN 70/30 do not: Drive or operate heavy machinery, until you know how HUMULIN 70/30 affects you. Drink alcohol or use prescription or over-the-counter medicines that contain alcohol. What are the possible side effects of HUMULIN 70/30? HUMULIN 70/30 may cause serious side effects that can lead to death, including: low blood sugar (hypoglycemia). Signs and symptoms that may indicate low blood sugar include: dizziness or light-headedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, or mood changes, hunger. serious allergic reaction (whole body reaction). Get medical help right away, if you have any of these symptoms of an allergic reaction: a rash over your whole body, trouble breathing, a fast heartbeat, or sweating. low potassium in your blood (hypokalemia). heart failure. Taking certain diabetes pills called thiazolidinediones or “TZDs” with HUMULIN 70/30 may cause heart failure in some people. This can happen even if you have never had heart failure or heart problems before. If you already have heart failure it may get worse while you use TZDs with HUMULIN 70/30. Your healthcare provider should monitor you closely while you are taking TZDs with HUMULIN 70/30. Tell your healthcare provider if you have any new or worse symptoms of heart failure including: shortness of breath, swelling of your ankles or feet, sudden weight gain Treatment with TZDs and HUMULIN 70/30 may need to be adjusted or stopped by your healthcare provider if you have new or worse heart failure. Get emergency medical help if you have: trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, confusion. The most common side effects of HUMULIN 70/30 include: low blood sugar (hypoglycemia), allergic reactions including reactions at the injection site, skin thickening or pits at the injection site (lipodystrophy), itching, rash, weight gain, and swelling of your hands and feet. These are not all the possible side effects of HUMULIN 70/30. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. General information about the safe and effective use of HUMULIN 70/30: Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about HUMULIN 70/30 that is written for health professionals. Do not use HUMULIN 70/30 for a condition for which it was not prescribed. Do not give HUMULIN 70/30 to other people, even if they have the same symptoms that you have. It may harm them. What are the ingredients in HUMULIN 70/30? Active Ingredient: insulin human (rDNA origin) Inactive Ingredients: protamine sulfate, glycerin, dibasic sodium phosphate, metacresol, phenol, zinc oxide, water for injection, hydrochloric acid or sodium hydroxide For more information, call 1-800-545-5979 or go to www.humulin.com. This Patient Information has been approved by the U.S. Food and Drug Administration. Instructions for Use HUMULIN® (HU-mu-lin) 70/30 (70% human insulin isophane suspension and 30% human insulin injection [rDNA origin]) vial (100 Units/mL, U-100) Read the Instructions for Use before you start taking HUMULIN 70/30 and each time you get a new HUMULIN 70/30 vial. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. Do not share your syringes or needles with anyone else. You may give an infection to them or get an infection from them. Supplies needed to give your injection: a HUMULIN 70/30 vial a U-100 insulin syringe and needle 2 alcohol swabs 1 sharps container for throwing away used needles and syringes. See “Disposing of used needles and syringes” at the end of these instructions. Preparing your HUMULIN 70/30 dose: Wash your hands with soap and water. Check the HUMULIN 70/30 label to make sure you are taking the right type of insulin. This is especially important if you use more than 1 type of insulin. Do not use HUMULIN 70/30 past the expiration date printed on the label or 31 days after you first use it. Always use a new needle for each injection to help ensure sterility and prevent blocked needles. Step 1: Gently roll the vial between the palms of your hands at least 10 times. Step 2: Invert the vial at least 10 times. Do not shake. Mixing is important to make sure you get the right dose. Humulin 70/30 should look white and cloudy after mixing. Do not use it if it looks clear or contains any lumps or particles. Step 3: If you are using a new vial, pull off the plastic Protective Cap, but do not remove the Rubber Stopper. Step 4: Wipe the Rubber Stopper with an alcohol swab. Step 5: Hold the syringe with the needle pointing up. Pull down on the Plunger until the tip of the Plunger reaches the line for the number of units for your prescribed dose. (Example Dose: 20 units shown) Step 6: Push the needle through the Rubber Stopper of the vial. Step 7: Push the plunger all the way in. This puts air into the vial. Step 8: Turn the vial and syringe upside down and slowly pull the Plunger down until the tip is a few units past the line for your prescribed dose. (Example Dose: 20 units Plunger is shown at 24 units)  If there are air bubbles, tap the syringe gently a few times to let any air bubbles rise to the top.  Step 9: Slowly push the Plunger up until the tip reaches the line for your prescribed dose. Check the syringe to make sure that you have the right dose. (Example Dose: 20 units shown) Step 10: Pull the syringe out of the vial's Rubber Stopper. Giving your HUMULIN 70/30 injection: Inject your insulin exactly as your healthcare provider has shown you. Change (rotate) your injection site for each injection. Step 11: Choose your injection site. HUMULIN 70/30 is injected under the skin (subcutaneously) of your stomach area (abdomen), buttocks, upper legs or upper arms. Wipe the skin with an alcohol swab. Let the injection site dry before you inject your dose.  Step 12: Insert the needle into your skin. Step 13: Push down on the Plunger to inject your dose. The needle should stay in your skin for at least 5 seconds to make sure you have injected all of your insulin dose. Step 14: Pull the needle out of your skin. If you see blood after you take the needle out of your skin, press the injection site with a piece of gauze or an alcohol swab. Do not rub the area. Do not recap the needle. Recapping the needle can lead to a needle stick injury. Disposing of used needles and syringes: Put your used needles and syringes in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles and syringes in your household trash. If you do not have a FDA-cleared sharps disposal container, you may use a household container that is: made of a heavy-duty plastic, can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, upright and stable during use, leak-resistant, and properly labeled to warn of hazardous waste inside the container. When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal Do not recycle the container. How should I store HUMULIN 70/30? All unopened HUMULIN 70/30 vials: Store all unopened vials in the refrigerator. Do not freeze. Do not use if it has been frozen. Keep away from heat and out of direct light. Unopened vials can be used until the expiration date on the carton and label, if they have been stored in the refrigerator. Unopened vials should be thrown away after 31 days, if they are stored at room temperature. After HUMULIN 70/30 vials have been opened: Store opened vials in the refrigerator or at room temperature below 86°F (30°C) for up to 31 days. Keep away from heat and out of direct light. Throw away all opened vials after 31 days of use, even if there is still insulin left in the vial. General information about the safe and effective use of HUMULIN 70/30. Keep HUMULIN 70/30 vials, syringes, needles, and all medicines out of the reach of children. If you have any questions or problems with your HUMULIN, contact Lilly at 1-800Lilly-Rx (1-800-545-5979) or call your healthcare provider for help. For moreinformation on HUMULIN and insulin, go to www.humulin.com. Scan this code to launch the humulin.com website This Instructions for Use has been approved by the U.S. Food and Drug Administration. Instructions for Use HUMULIN® 70/30 KwikPen™ (70% human insulin isophane suspension 30% human insulin injection [rDNA origin]) Read the Instructions for Use before you start taking HUMULIN 70/30 and each time you get another HUMULIN® 70/30 KwikPen™. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. HUMULIN 70/30 KwikPen (“Pen”) is a disposable pen containing 3 mL (300 units) of U-100 HUMULIN® 70/30 (70% human insulin isophane suspension and 30% human insulin injection [rDNA origin]) insulin. You can inject from 1 to 60 units in a single injection. HUMULIN 70/30 KwikPen has a blue and brown Label with a matching brown Dose Knob (See the KwikPen Parts diagram below). Do not share your HUMULIN 70/30 KwikPen or needles with another person. You may give an infection to them or get an infection from them. This Pen is not recommended for use by the blind or visually impaired without the assistance of a person trained in the proper use of the product. KwikPen Parts Supplies you will need to give your HUMULIN 70/30 injection: HUMULIN 70/30 KwikPen KwikPen compatible Needle (Becton, Dickinson and Company Pen Needles recommended) alcohol swab Preparing HUMULIN 70/30 KwikPen: Wash your hands with soap and water. Check the HUMULIN 70/30 KwikPen Label to make sure you are taking the right type of insulin. This is especially important if you use more than 1 type of insulin. Do not use HUMULIN 70/30 past the expiration date printed on the Label or 10 days after you start using the Pen. Always use a new needle for each injection to help ensure sterility and prevent blocked needles. Step 1: Pull the Pen Cap straight off. Wipe the Rubber Seal with an alcohol swab. Do not twist the cap. Do not remove the HUMULIN 70/30 KwikPen Label. Do not attach the Needle before mixing. Step 2: Gently roll the Pen between your hands 10 times. Step 3: Move the Pen up and down (invert) the Pen 10 times. Mixing by rolling and inverting the Pen is important to make sure you get the right dose. Step 4: Check the liquid in the Pen. HUMULIN 70/30 should look white and cloudy after mixing. Do not use if it looks clear or has any lumps or particles in it. Step 5: Select a new Needle. Pull off the Paper Tab from the Outer Needle Shield. Step 6: Push the capped Needle straight onto the Pen and twist the Needle on until it is tight. Step 7: Pull off the Outer Needle Shield. Do not throw it away. Pull off the Inner Needle Shield and throw it away. Priming the HUMULIN 70/30 KwikPen: Prime the HUMULIN 70/30 KwikPen before each injection. Priming ensures the Pen is ready to dose and removes air that may collect in the cartridge during normal use. If you do not prime before each injection, you may get too much or too little insulin. Step 8: Turn the Dose Knob to select 2 units. Step 9: Hold the Pen with the Needle pointing up. Tap the Cartridge Holder gently to collect air bubbles at the top. Step 10: Hold the Pen with Needle pointing up. Push the Dose Knob in until it stops, and “0” is seen in the Dose Window. Hold the Dose Knob in and count to 5 slowly. A stream of insulin should be seen from the needle. If you do not see a stream of insulin, repeat steps 8 to 10, no more than 4 times. If you still do not see a stream of insulin, change the needle and repeat steps 8 to 10. Selecting your dose: Step 11: Turn the Dose Knob to select the number of units you need to inject. The Dose Indicator should line up with your dose. The dose can be corrected by turning the Dose Knob in either direction until the correct dose lines up with the Dose Indicator. The even numbers are printed on the dial. (Example: 10 units shown) The odd numbers, after the number 1, are shown as full lines (Example: 15 units shown) The HUMULIN 70/30 KwikPen will not let you dial more than the number of units left in the Pen. If your dose is more than the number of units left in the Pen, you may either: inject the amount left in your Pen and then use a new Pen to give the rest of your dose, or get a new Pen and inject the full dose. The Pen is designed to deliver a total of 300 units of insulin. The cartridge contains an additional small amount of insulin that cannot be delivered. Giving your HUMULIN 70/30 injection: Inject your HUMULIN 70/30 exactly as your healthcare provider has shown you. Change (rotate) your injection site for each injection. Do not try to change your dose while injecting HUMULIN 70/30. Step 12: Choose your injection site. HUMULIN 70/30 is injected under the skin (subcutaneously) of your stomach area, buttocks, upper legs or upper arms. Wipe the skin with an alcohol swab, and let the injection site dry before you inject your dose. Step 13: Insert the Needle into your skin. Step 14: Put your thumb on the Dose Knob and push the Dose Knob in until it stops. Hold the Dose Knob in and slowly count to 5. Step 15: Pull the Needle out of your skin. You should see “0” in the Dose Window. If you do not see “0” in the Dose Window, you did not receive your full dose. If you see blood after you take the Needle out of your skin, press the injection site lightly with a piece of gauze or an alcohol swab. Do not rub the area. A drop of insulin at the needle tip is normal. It will not affect your dose. If you do not think you received your full dose, do not take another dose. Call Lilly at 1-800-LillyRx (1-800-545-5979) or your healthcare provider for help. Step 16: Carefully replace the Outer Needle Shield. Step 17: Unscrew the capped Needle and throw it away. Do not store the Pen with the Needle attached to prevent leaking, blocking of the Needle, and air from entering the Pen. Step 18: Replace the Pen Cap by lining up the Cap Clip with the Dose Indicator and pushing straight on. After your injection: Put your used needles and pens in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles and pens in your household trash. If you do not have a FDA-cleared sharps disposal container, you may use a household container that is: made of a heavy-duty plastic, can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, upright and stable during use, leak-resistant, and properly labeled to warn of hazardous waste inside the container. When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal How should I store my HUMULIN 70/30 KwikPen? Store unused HUMULIN 70/30 KwikPens in the refrigerator at 36°F to 46°F (2°C to 8°C). The Pen you are currently using should be stored at room temperature, below 86°F (30°C). Do not freeze HUMULIN 70/30. Do not use HUMULIN 70/30 if it has been frozen. Unused Pens may be used until the expiration date printed on the Label, if kept in the refrigerator. The HUMULIN 70/30 Pen you are using should be thrown away after 10 days, even if it still has insulin left in it. Keep HUMULIN 70/30 away from heat and out of the light. General information about the safe and effective use of HUMULIN 70/30 KwikPen. Keep HUMULIN 70/30 KwikPen and needles out of the reach of children. Do not use the Pen if any part looks broken or damaged. Always carry an extra Pen in case yours is lost or damaged. If you cannot remove the Pen Cap, gently twist the Pen Cap back and forth, and then pull the Pen Cap straight off. If it is hard to push the Dose Knob or the Pen is not working the right way: Your Needle may be blocked. Put on a new Needle and prime the Pen. You may have dust, food, or liquid inside the Pen. Throw the Pen away and get a new one. It may help to push the Dose Knob more slowly during your injection. Use the space below to keep track of how long you should use each HUMULIN 70/30 KwikPen. Write down the date you start using your HUMULIN 70/30 KwikPen. Count forward 10 days. Write down the date you should throw it away. Example: First used on _______ + 10 days = Throw out on ______ Pen 1 -First used on _______ Throw out on _______ _________________Date_______________Date Pen 2 -First used on _______ Throw out on _______ _________________Date_______________Date Pen 3 -First used on _______ Throw out on _______ _________________Date_______________Date Pen 4 -First used on _______ Throw out on _______ _________________Date_______________Date Pen 5 -First used on _______ Throw out on _______ _________________Date_______________Date If you have any questions or problems with your HUMULIN 70/30 KwikPen, contact Lilly at 1-800-LillyRx (1-800-545-5979) or call your healthcare provider for help. For more information on HUMULIN 70/30 KwikPen and insulin, go to www.lilly.com. This Instructions for Use has been approved by the U.S. Food and Drug Administration.

OVERDOSE Excess insulin may cause hypoglycemia and hypokalemia, particularly after intravenous administration. Hypoglycemia may occur as a result of an excess of insulin relative to food intake, energy expenditure, or both. Mild episodes of hypoglycemia usually can be treated with oral glucose. Adjustments in drug dosage, meal patterns, or exercise may be needed. More severe episodes with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycemia may recur after apparent clinical recovery. Hypokalemia must be corrected appropriately. CONTRAINDICATIONS Humulin R (insulin (human recombinant)) U-100 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Humulin R (insulin (human recombinant)) U-100 or any of its excipients.

SIDE EFFECTS The following adverse reactions are discussed elsewhere in the labeling: Hypoglycemia [see WARNINGS AND PRECAUTIONS]. Hypokalemia [see WARNINGS AND PRECAUTIONS]. The following additional adverse reactions have been identified during post-approval use of HUMULIN N. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure. Allergic Reactions Some patients taking HUMULIN N have experienced erythema, local edema, and pruritus at the site of injection. These conditions were usually self-limiting. Severe cases of generalized allergy (anaphylaxis) have been reported [see WARNINGS AND PRECAUTIONS]. Peripheral Edema Some patients taking HUMULIN N have experienced sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Lipodystrophy Administration of insulin subcutaneously, including HUMULIN N, has resulted in lipoatrophy (depression in the skin) or lipohypertrophy (enlargement or thickening of tissue) [see DOSAGE AND ADMINISTRATION] in some patients. Weight gain Weight gain has occurred with some insulin therapies including HUMULIN N and has been attributed to the anabolic effects of insulin and the decrease in glycosuria. Immunogenicity Development of antibodies that react with human insulin have been observed with all insulin, including HUMULIN N. DRUG INTERACTIONS Drugs That May Increase The Risk Of Hypoglycemia The risk of hypoglycemia associated with HUMULIN N use may be increased when co-administered with antidiabetic agents, salicylates, sulfonamide antibiotics, monoamine oxidase inhibitors, fluoxetine, disopyramide, fibrates, propoxyphene, pentoxifylline, ACE inhibitors, angiotensin II receptor blocking agents, and somatostatin analogs (e.g., octreotide). Dose adjustment and increased frequency of glucose monitoring may be required when HUMULIN N is co-administered with these drugs. Drugs That May Decrease The Blood Glucose Lowering Effect Of HUMULIN N The glucose lowering effect of HUMULIN N may be decreased when co-administered with corticosteroids, isoniazid, niacin, estrogens, oral contraceptives, phenothiazines, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), somatropin, atypical antipsychotics, glucagon, protease inhibitors, and thyroid hormones. Dose adjustment and increased frequency of glucose monitoring may be required when HUMULIN N is co-administered with these drugs. Drugs That May Increase Or Decrease The Blood Glucose Lowering Effect Of HUMULIN N The glucose lowering effect of HUMULIN N may be increased or decreased when co-administered with beta-blockers, clonidine, lithium salts, and alcohol. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia. Dose adjustment and increased frequency of glucose monitoring may be required when HUMULIN N is co-administered with these drugs. Drugs That May Blunt Signs And Symptoms Of Hypoglycemia The signs and symptoms of hypoglycemia [see WARNINGS AND PRECAUTIONS] may be blunted when beta-blockers, clonidine, guanethidine, and reserpine are co-administered with HUMULIN N.

SIDE EFFECTS The following adverse reactions are discussed elsewhere in the labeling: Hypoglycemia [see WARNINGS AND PRECAUTIONS]. Hypokalemia [see WARNINGS AND PRECAUTIONS]. The following additional adverse reactions have been identified during post-approval use of HUMULIN 70/30. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure. Allergic Reactions Some patients taking HUMULIN 70/30 have experienced erythema, local edema, and pruritus at the site of injection. These conditions were usually self-limiting. Severe cases of generalized allergy (anaphylaxis) have been reported [see WARNINGS AND PRECAUTIONS]. Peripheral Edema Some patients taking HUMULIN 70/30 have experienced sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Lipodystrophy Administration of insulin subcutaneously, including HUMULIN 70/30, has resulted in lipoatrophy (depression in the skin) or lipohypertrophy (enlargement or thickening of tissue) [see DOSAGE AND ADMINISTRATION] in some patients. Weight gain Weight gain has occurred with some insulin therapies including HUMULIN 70/30 and has been attributed to the anabolic effects of insulin and the decrease in glycosuria. Immunogenicity Development of antibodies that react with human insulin have been observed with all insulin, including HUMULIN 70/30. DRUG INTERACTIONS Drugs That May Increase The Risk Of Hypoglycemia The risk of hypoglycemia associated with HUMULIN 70/30 use may be increased when co-administered with antidiabetic agents, salicylates, sulfonamide antibiotics, monoamine oxidase inhibitors, fluoxetine, disopyramide, fibrates, propoxyphene, pentoxifylline, ACE inhibitors, angiotensin II receptor blocking agents, and somatostatin analogs (e.g., octreotide). Dose adjustment and increased frequency of glucose monitoring may be required when HUMULIN 70/30 is co-administered with these drugs. Drugs That May Decrease The Blood Glucose Lowering Effect Of HUMULIN 70/30 The glucose lowering effect of HUMULIN 70/30 may be decreased when co-administered with corticosteroids, isoniazid, niacin, estrogens, oral contraceptives, phenothiazines, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), somatropin, atypical antipsychotics, glucagon, protease inhibitors, and thyroid hormones. Dose adjustment and increased frequency of glucose monitoring may be required when HUMULIN 70/30 is co-administered with these drugs. Drugs That May Increase Or Decrease The Blood Glucose Lowering Effect Of HUMULIN 70/30 The glucose lowering effect of HUMULIN 70/30 may be increased or decreased when co-administered with beta-blockers, clonidine, lithium salts, and alcohol. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia. Dose adjustment and increased frequency of glucose monitoring may be required when HUMULIN 70/30 is co-administered with these drugs. Drugs That May Blunt Signs And Symptoms Of Hypoglycemia The signs and symptoms of hypoglycemia [see WARNINGS AND PRECAUTIONS] may be blunted when beta-blockers, clonidine, guanethidine, and reserpine are co-administered with HUMULIN 70/30.

WARNINGS Any change in insulin should be made cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type (e.g., regular, NPH, analog, etc.), species, or method of administration may result in the need for a change in dosage. PRECAUTIONS Hypoglycemia Hypoglycemia is the most common adverse reaction of all insulin therapies, including Humulin R (insulin (human recombinant)) U-100. Severe hypoglycemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or death. Severe hypoglycemia requiring the assistance of another person and/or parenteral glucose infusion or glucagon administration has been observed in clinical trials with insulin, including trials with Humulin R (insulin (human recombinant)) U-100. As with all insulin preparations, the time course of Humulin R (insulin (human recombinant)) U-100 action may vary in different individuals or at different times in the same individual and is dependent on dose, site of injection, blood supply, temperature, and physical activity. Adjustment of dosage of any insulin may be necessary if patients change their physical activity or their usual meal plan. Insulin requirements may be altered during illness, emotional disturbances, or other stresses. Concomitant antihyperglycemic agents may need to be adjusted. The timing of hypoglycemia usually reflects the time-action profile of the administered insulin formulations. Other factors such as changes in food intake (e.g., amount of food or timing of meals), injection site, exercise, and concomitant medications may also alter the risk of hypoglycemia (See PRECAUTIONS: DRUG INTERACTIONS). As with all insulins, use caution in patients with hypoglycemia unawareness and in patients who may be predisposed to hypoglycemia (e.g., the pediatric population and patients who fast or have erratic food intake). The patient's ability to concentrate and react may be impaired as a result of hypoglycemia. This may present a risk in situations where these abilities are especially important, such as driving or operating other machinery. Hyperglycemia, Diabetic Ketoacidosis, and Hyperosmolar Non-Ketotic Syndrome Hyperglycemia, diabetic ketoacidosis, or hyperosmolar coma may develop if the patient takes less Humulin R (insulin (human recombinant)) U-100 than needed to control blood glucose levels. This could be due to increases in insulin demand during illness or infection, neglect of diet, omission or improper administration of prescribed insulin doses or use of drugs that affect glucose metabolism or insulin sensitivity. Early signs of diabetic ketoacidosis include glycosuria and ketonuria. Polydipsia, polyuria, loss of appetite, fatigue, dry skin, abdominal pain, nausea and vomiting and compensatory tachypnea come on gradually, usually over a period of some hours or days, in conjunction with hyperglycemia and ketonemia. Severe sustained hyperglycemia may result in hyperosmolar coma or death. Hypokalemia Insulin stimulates potassium movement into the cells, possibly leading to hypokalemia, that left untreated may cause respiratory paralysis, ventricular arrhythmia, and death. Since intravenously administered insulin has a rapid onset of action, increased attention to hypokalemia is necessary. Therefore, potassium levels must be monitored closely when Humulin R (insulin (human recombinant)) U-100 or any other insulin is administered intravenously. Use caution in patients who may be at risk for hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations). Hypersensitivity and Allergic Reactions Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Humulin R U-100 (see ADVERSE REACTIONS). Localized reactions and generalized myalgias have been reported with the use of metacresol as an injectable excipient. Renal or Hepatic Impairment Frequent glucose monitoring and insulin dose reduction may be required in patients with renal or hepatic impairment. Drug Interactions Some medications may alter insulin requirements and the risk for hypoglycemia and hyperglycemia (see DRUG INTERACTIONS). Use in Pregnancy Pregnancy Category B. All pregnancies have a background risk of birth defects, miscarriage, or other adverse outcome regardless of drug exposure. This background risk is increased in pregnancies complicated by hyperglycemia and is decreased with good glucose control. It is important for patients to maintain good control of diabetes before conception and during pregnancy. Special attention should be paid to diet, exercise and insulin regimens. Insulin requirements may decrease during the first trimester, usually increase during the second and third trimesters, and rapidly decline after delivery. Careful monitoring is essential in these patients. Female patients should be advised to tell their physician if they intend to become, or if they become pregnant. Studies show that endogenous insulin only crosses the placenta in minimal amounts. While there are no adequate and well-controlled studies in pregnant women, an extensive body of published literature demonstrates the maternal and fetal benefits of insulin treatment in patients with diabetes during pregnancy. Humulin R (insulin (human recombinant)) is a recombinant human insulin that is identical to the endogenous hormone; therefore, reproduction and fertility studies were not performed in animals. Labor and Delivery Careful glucose monitoring and management of patients with diabetes during labor and delivery are required. Nursing Mothers Endogenous insulin is present in human milk. Insulin orally ingested is degraded in the gastrointestinal tract. No adverse reactions have been associated with infant exposure to insulin through the consumption of human milk. In a study of eight preterm infants between 26 to 30 weeks gestation, enteral administration of Humulin R (insulin (human recombinant)) did not result in hypoglycemia. Good glucose control supports lactation in patients with diabetes. Patients with diabetes who are lactating may require adjustments in insulin dose and/or diet.

WARNINGS Included as part of the PRECAUTIONS section. PRECAUTIONS Changes In Insulin Regimen Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously and under close medical supervision and the frequency of blood glucose monitoring should be increased. Hypoglycemia Hypoglycemia is the most common adverse reaction associated with insulins, including HUMULIN N. Severe hypoglycemia can cause seizures, may be life-threatening or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). Hypoglycemia can happen suddenly and symptoms may differ in each individual and change over time in the same individual. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic nerve disease, in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) [see DRUG INTERACTIONS], or in patients who experience recurrent hypoglycemia. Risk Factors for Hypoglycemia The risk of hypoglycemia after an injection is related to the duration of action of the insulin and, in general, is highest when the glucose lowering effect of the insulin is maximal. As with all insulin preparations, the glucose lowering effect time course of HUMULIN N may vary in different individuals or at different times in the same individual and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature [see CLINICAL PHARMACOLOGY]. Other factors which may increase the risk of hypoglycemia include changes in meal pattern (e.g., macronutrient content or timing of meals), changes in level of physical activity, or changes to co-administered medication [see DRUG INTERACTIONS]. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia [see Use In Specific Populations]. Risk Mitigation Strategies for Hypoglycemia Patients and caregivers must be educated to recognize and manage hypoglycemia. Self-monitoring of blood glucose plays an essential role in the prevention and management of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended. Hypersensitivity Reactions Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including HUMULIN N. If hypersensitivity reactions occur, discontinue HUMULIN N; treat per standard of care and monitor until symptoms and signs resolve [see ADVERSE REACTIONS]. HUMULIN N is contraindicated in patients who have had hypersensitivity reactions to HUMULIN N or any of its excipients [see CONTRAINDICATIONS]. Hypokalemia All insulin products, including HUMULIN N, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia if indicated (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations). Fluid Retention And Heart Failure With Concomitant Use Of PPAR-gamma Agonists Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. Patients treated with insulin, including HUMULIN N, and a PPAR-gamma agonist should be observed for signs and symptoms of heart failure. If heart failure develops, it should be managed according to current standards of care, and discontinuation or dose reduction of the PPAR-gamma agonist must be considered. Patient Counseling Information Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use). Hypoglycemia Instruct patients on self-management procedures including glucose monitoring, proper injection technique, and management of hypoglycemia and hyperglycemia especially at initiation of HUMULIN N therapy. Instruct patients on handling of special situations such as intercurrent conditions (illness, stress, or emotional disturbances), an inadequate or skipped insulin dose, inadvertent administration of an increased insulin dose, inadequate food intake, and skipped meals. Instruct patients on the management of hypoglycemia. Inform patients that their ability to concentrate and react may be impaired as a result of hypoglycemia. Advise patients who have frequent hypoglycemia or reduced or absent warning signs of hypoglycemia to use caution when driving or operating machinery [see WARNINGS AND PRECAUTIONS]. Inform patients that accidental mix-ups between HUMULIN N and other insulins have been reported. Instruct patients to always carefully check that they are administering the correct insulin (e.g., by checking the insulin label before each injection) to avoid medication errors between HUMULIN N and other insulins. Hypersensitivity Reactions Advise patients that hypersensitivity reactions have occurred with HUMULIN N. Inform patients on the symptoms of hypersensitivity reactions [see WARNINGS AND PRECAUTIONS]. Females with Reproductive Potential Advise females of reproductive potential with diabetes to inform their doctor if they are pregnant or are contemplating pregnancy [see Use In Specific Populations]. Visual Inspection Prior to Use Instruct patients to visually inspect HUMULIN N before use and to use HUMULIN N only if it contains no particulate matter and appears uniformly cloudy after mixing [see DOSAGE AND ADMINISTRATION]. Expiration Date Instruct patients not to use HUMULIN N after the printed expiration date. Nonclinical Toxicology Carcinogenesis, Mutagenesis, Impairment Of Fertility Carcinogenicity and fertility studies were not performed in animals. Biosynthetic human insulin was not genotoxic in the in vivo sister chromatid exchange assay and the in vitro gradient plate and unscheduled DNA synthesis assays. Use In Specific Populations Pregnancy Pregnancy Category B Risk Summary All pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. This background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. It is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy. In patients with diabetes or gestational diabetes, insulin requirements may decrease during the first trimester, generally increase during the second and third trimesters, and rapidly decline after delivery. Careful monitoring of glucose control is essential in these patients. Therefore, female patients should be advised to tell their physicians if they intend to become, or if they become pregnant while taking HUMULIN N. Human Data While there are no adequate and well-controlled studies of HUMULIN N in pregnant women, evidence from published literature suggests that good glycemic control in patients with diabetes during pregnancy provides significant maternal and fetal benefits. Animal Data Reproduction and fertility toxicity studies were not performed in animals. Nursing Mothers Endogenous insulin is present in human milk; it is unknown whether HUMULIN N is present in human milk. Insulin orally ingested is degraded in the gastrointestinal tract. No adverse reactions associated with infant exposure to insulin through the consumption of human milk have been reported. Good glucose control supports lactation in patients with diabetes. Women with diabetes who are lactating may require adjustments in their insulin dose. Pediatric Use HUMULIN N has not been studied in pediatric patients. As in adults, the dosage of HUMULIN N in pediatric patients must be individualized based on metabolic needs, treatment goal and blood glucose monitoring results. Geriatric Use The effect of age on the pharmacokinetics and pharmacodynamics of HUMULIN N has not been studied [see CLINICAL PHARMACOLOGY]. Patients with advanced age using any insulin, including HUMULIN N, may be at increased risk of hypoglycemia due to co-morbid disease and polypharmacy [see WARNINGS AND PRECAUTIONS]. Renal Impairment The effect of renal impairment on the pharmacokinetics and pharmacodynamics of HUMULIN N has not been studied [see CLINICAL PHARMACOLOGY]. Patients with renal impairment are at increased risk of hypoglycemia and may require more frequent HUMULIN N dose adjustment and more frequent blood glucose monitoring. Hepatic Impairment The effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of HUMULIN N has not been studied [see CLINICAL PHARMACOLOGY]. Patients with hepatic impairment are at increased risk of hypoglycemia and may require more frequent HUMULIN N dose adjustment and more frequent blood glucose monitoring.

WARNINGS Included as part of the PRECAUTIONS section. PRECAUTIONS Changes In Insulin Regimen Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia [see During episodes of hypoglycemia] or hyperglycemia. These changes should be made cautiously and under close medical supervision and the frequency of blood glucose monitoring should be increased. Hypoglycemia Hypoglycemia is the most common adverse reaction associated with insulins, including HUMULIN 70/30. Severe hypoglycemia can cause seizures, may be life-threatening or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). Hypoglycemia can happen suddenly and symptoms may differ in each individual and change over time in the same individual. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic nerve disease, in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) [see DRUG INTERACTIONS], or in patients who experience recurrent hypoglycemia. Risk Factors for Hypoglycemia The risk of hypoglycemia after an injection is related to the duration of action of the insulin and, in general, is highest when the glucose lowering effect of the insulin is maximal. As with all insulin preparations, the glucose lowering effect time course of HUMULIN 70/30 may vary in different individuals or at different times in the same individual and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature [see CLINICAL PHARMACOLOGY]. Other factors which may increase the risk of hypoglycemia include changes in meal pattern (e.g., macronutrient content or timing of meals), changes in level of physical activity, or changes to co-administered medication [see DRUG INTERACTIONS]. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia [see Use In Specific Populations]. Risk Mitigation Strategies for Hypoglycemia Patients and caregivers must be educated to recognize and manage hypoglycemia. Self-monitoring of blood glucose plays an essential role in the prevention and management of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended. Hypersensitivity Reactions Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including HUMULIN 70/30. If hypersensitivity reactions occur, discontinue HUMULIN 70/30; treat per standard of care and monitor until symptoms and signs resolve [see ADVERSE REACTIONS]. HUMULIN 70/30 is contraindicated in patients who have had hypersensitivity reactions to HUMULIN 70/30 or any of its excipients [see CONTRAINDICATIONS]. Hypokalemia All insulin products, including HUMULIN 70/30, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia if indicated (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations). Fluid Retention And Heart Failure With Concomitant Use Of PPAR-gamma Agonists Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. Patients treated with insulin, including HUMULIN 70/30, and a PPAR-gamma agonist should be observed for signs and symptoms of heart failure. If heart failure develops, it should be managed according to current standards of care, and discontinuation or dose reduction of the PPAR-gamma agonist must be considered. Patient Counseling Information Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use). Hypoglycemia Instruct patients on self-management procedures including glucose monitoring, proper injection technique, and management of hypoglycemia and hyperglycemia especially at initiation of HUMULIN 70/30 therapy. Instruct patients on handling of special situations such as intercurrent conditions (illness, stress, or emotional disturbances), an inadequate or skipped insulin dose, inadvertent administration of an increased insulin dose, inadequate food intake, and skipped meals. Instruct patients on the management of hypoglycemia. Inform patients that their ability to concentrate and react may be impaired as a result of hypoglycemia. Advise patients who have frequent hypoglycemia or reduced or absent warning signs of hypoglycemia to use caution when driving or operating machinery [see WARNINGS AND PRECAUTIONS]. Inform patients that accidental mix-ups between HUMULIN 70/30 and other insulins have been reported. Instruct patients to always carefully check that they are administering the correct insulin (e.g., by checking the insulin label before each injection) to avoid medication errors between HUMULIN 70/30 and other insulins. Hypersensitivity Reactions Advise patients that hypersensitivity reactions have occurred with HUMULIN 70/30. Inform patients on the symptoms of hypersensitivity reactions [see WARNINGS AND PRECAUTIONS]. Females with Reproductive Potential Advise females of reproductive potential with diabetes to inform their doctor if they are pregnant or are contemplating pregnancy [see Use In Specific Populations]. Visual Inspection Prior to Use Instruct patients to visually inspect HUMULIN 70/30 before use and to use HUMULIN 70/30 only if it contains no particulate matter and appears uniformly cloudy after mixing [see DOSAGE AND ADMINISTRATION]. Expiration Date Instruct patients not to use HUMULIN 70/30 after the printed expiration date. Nonclinical Toxicology Carcinogenesis, Mutagenesis, Impairment Of Fertility Carcinogenicity and fertility studies were not performed in animals. Biosynthetic human insulin was not genotoxic in the in vivo sister chromatid exchange assay and the in vitro gradient plate and unscheduled DNA synthesis assays. Use In Specific Populations Pregnancy Pregnancy Category B Risk Summary All pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. This background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. It is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy. In patients with diabetes or gestational diabetes, insulin requirements may decrease during the first trimester, generally increase during the second and third trimesters, and rapidly decline after delivery. Careful monitoring of glucose control is essential in these patients. Therefore, female patients should be advised to tell their physicians if they intend to become, or if they become pregnant while taking HUMULIN 70/30. Human Data While there are no adequate and well-controlled studies of HUMULIN 70/30 in pregnant women, evidence from published literature suggests that good glycemic control in patients with diabetes during pregnancy provides significant maternal and fetal benefits. Animal Data Reproduction and fertility toxicity studies were not performed in animals. Nursing Mothers Endogenous insulin is present in human milk; it is unknown whether HUMULIN 70/30 is present in human milk. Insulin orally ingested is degraded in the gastrointestinal tract. No adverse reactions associated with infant exposure to insulin through the consumption of human milk have been reported. Good glucose control supports lactation in patients with diabetes. Women with diabetes who are lactating may require adjustments in their insulin dose. Pediatric Use Safety and effectiveness of HUMULIN 70/30 in patients less than 18 years of age has not been established. Geriatric Use The effect of age on the pharmacokinetics and pharmacodynamics of HUMULIN 70/30 has not been studied [see CLINICAL PHARMACOLOGY]. Patients with advanced age using any insulin, including HUMULIN 70/30, may be at increased risk of hypoglycemia due to co-morbid disease and polypharmacy [see WARNINGS AND PRECAUTIONS]. Renal Impairment The effect of renal impairment on the pharmacokinetics and pharmacodynamics of HUMULIN 70/30 has not been studied [see CLINICAL PHARMACOLOGY]. Patients with renal impairment are at increased risk of hypoglycemia and may require more frequent HUMULIN 70/30 dose adjustment and more frequent blood glucose monitoring. Hepatic Impairment The effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of HUMULIN 70/30 has not been studied [see CLINICAL PHARMACOLOGY]. Patients with hepatic impairment are at increased risk of hypoglycemia and may require more frequent HUMULIN 70/30 dose adjustment and more frequent blood glucose monitoring.